- Home
- AGEN vs IMAB Comparison
AGEN vs IMAB Comparison
Compare AGEN & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- IMAB
- Stock Information
- Founded
- AGEN 1994
- IMAB 2014
- Country
- AGEN United States
- IMAB United States
- Employees
- AGEN N/A
- IMAB N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- AGEN Health Care
- IMAB Health Care
- Exchange
- AGEN Nasdaq
- IMAB Nasdaq
- Market Cap
- AGEN 96.2M
- IMAB 83.8M
- IPO Year
- AGEN 2000
- IMAB 2020
- Fundamental
- Price
- AGEN $2.83
- IMAB $0.92
- Analyst Decision
- AGEN Buy
- IMAB Strong Buy
- Analyst Count
- AGEN 3
- IMAB 3
- Target Price
- AGEN $10.50
- IMAB $8.00
- AVG Volume (30 Days)
- AGEN 566.5K
- IMAB 452.7K
- Earning Date
- AGEN 11-12-2024
- IMAB 08-28-2024
- Dividend Yield
- AGEN N/A
- IMAB N/A
- EPS Growth
- AGEN N/A
- IMAB N/A
- EPS
- AGEN N/A
- IMAB N/A
- Revenue
- AGEN $160,427,000.00
- IMAB $3,313,984.00
- Revenue This Year
- AGEN N/A
- IMAB N/A
- Revenue Next Year
- AGEN $36.13
- IMAB N/A
- P/E Ratio
- AGEN N/A
- IMAB N/A
- Revenue Growth
- AGEN 59.00
- IMAB N/A
- 52 Week Low
- AGEN $2.50
- IMAB $0.90
- 52 Week High
- AGEN $19.69
- IMAB $2.54
- Technical
- Relative Strength Index (RSI)
- AGEN 39.40
- IMAB 38.53
- Support Level
- AGEN $2.65
- IMAB $0.90
- Resistance Level
- AGEN $3.85
- IMAB $0.98
- Average True Range (ATR)
- AGEN 0.29
- IMAB 0.07
- MACD
- AGEN -0.02
- IMAB -0.00
- Stochastic Oscillator
- AGEN 15.00
- IMAB 10.00
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).